Trials / Completed
CompletedNCT04672252
The Use of Cannabidiol (CBD) in Pain Reduction and Opioid Use After Shoulder Arthroscopy
The Use of Cannabidiol (CBD) in Pain Reduction and Opioid Use After Shoulder Arthroscopy; A Double-Blind, Randomized Control Study
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- NYU Langone Health · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate the effects of administering CBD to control post-operative pain in patients undergoing shoulder arthroscopy. Secondly, the purpose will be to evaluate the effectiveness of CBD in comparison with opioid therapy for post-operative pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CBD Oral Disintegrating Tablet (ODT) | Cohort 1: CBD ODTs to be administered with routine post-operative pain management regimen |
| OTHER | Placebo ODT | Cohort 2 will not receive CBD; but a visually indistinguishable placebo ODT instead. The resident physician, physician assistant, anesthesiologist, surgeon and study team members will remain blinded. Additionally, all patients will receive a traditional upper extremity interscalene block as per routine. |
Timeline
- Start date
- 2020-12-01
- Primary completion
- 2021-12-16
- Completion
- 2022-12-16
- First posted
- 2020-12-17
- Last updated
- 2023-03-07
- Results posted
- 2023-03-07
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04672252. Inclusion in this directory is not an endorsement.